Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Steven R Feldman¹, Yang Zhao², Lizheng Shi³, Jackie Lu² and MaryHelen Tran², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Tulane University, New Orleans, LA
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1543 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
Alvin Wells¹, Adewale O. Adebajo², Jacob A. Aelion³, Paul Bird⁴, Alan Kivitz⁵, Frédéric Lioté⁶, Piercarlo Sarzi-Puttini⁷, ChiaChi Hu⁸, Randall M. Stevens⁸ and Christopher J. Edwards⁹, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University of Sheffield, Sheffield, United Kingdom, ³West Tennessee Research Institute, Jackson, TN, ⁴Combined Rheumatology Practice, Kogarah, Australia, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁷Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁸Celgene Corporation, Warren, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE…
Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José M. Senabre-Gallego¹, José Rosas-Gómez de Salazar¹, Esteban Salas-Heredia¹, Gregorio Santos-Soler¹, Francisca Llinares-Tello², Carlos Santos-Ramirez³, Mabel Sánchez-Barrioluengo⁴, Xavier Barber-Vallés⁵, Rafaela Ortega³, Ana Pons¹, Catalina Cano¹ and Maria Luisa Lorente-Betoret¹, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Salud, Denia, Spain, ⁴Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, ⁵Center of Operations Research, University Miguel Hernández, Elche, Spain
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Proton Rahman¹, Denis Choquette², William Bensen³, Majed Khraishi⁴, Saeed Shaikh⁵, Regan Arendse⁶, Isabelle Fortin⁷, Andrew Chow⁸, Maqbool Sheriff⁹, Eliofotisti Psaradellis¹⁰, John S. Sampalis¹⁰, Susan Otawa¹¹, Francois Nantel¹², Allen J Lehman¹¹ and May Shawi¹², ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 1561 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Georg A. Schett¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jurgen Wollenhaupt⁷, Maurizio Cutolo⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, La Jolla, CA, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁷Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University Hospital Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps to regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 2140 • 2014 ACR/ARHP Annual Meeting
Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis
Alexis Ogdie¹, Shiv Sehra², Viviane Khoury³, Yihui Jiang⁴, Shawn Rose⁵, Nehal N. Mehta⁶, Sally W. Pullman-Mooar⁷, Abass Alavi⁸, Joel Gelfand⁹ and Joshua Baker¹⁰, ¹Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Department of Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, ⁷Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ⁸Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, ⁹Dermatology and Epidemiology, University of Pennsylvania., Philadelphia, PA, ¹⁰Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA
Background/Purpose: The lack of tools to accurately measure and quantify joint inflammation is a challenging problem in the study of inflammatory arthritis. No gold standard…
Abstract Number: 1150 • 2014 ACR/ARHP Annual Meeting
Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation
Anna Cooper¹, Johan A. Karlsson² and Anders Gülfe¹, ¹Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden, ²Dept of Clinical Sciences, Section for Rheumatology, Lund University, Faculty of Medicine, Lund, Sweden
Background/Purpose: Health related quality of life (HRQoL) can be expressed as utility, a value anchored at 0 (death) and 1 (perfect health, forming the basis…
Abstract Number: 1963 • 2014 ACR/ARHP Annual Meeting
Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis
Siba Raychaudhuri¹, Anupam Mitra², Ananya Datta Mitra³, Christine Abria⁴ and Smriti K. Raychaudhuri³, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Research, VA Sacramento Medical Center, Mather, CA
Background/Purpose: The PI3K/Akt/mTOR signaling proteins are pro-growth/pro-survival and thus likely to regulate inflammatory cascades in autoimmune diseases (1). The key pathologic outcome in psoriatic arthritis…
Abstract Number: 953 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study
Philip J. Mease¹, Iain B. McInnes², Bruce Kirkham³, Arthur Kavanaugh⁴, Proton Rahman⁵, Désirée van der Heijde⁶, Robert Landewé⁷, Peter Nash⁸, Luminita Pricop⁹, Jiacheng Yuan¹⁰, Hanno Richards¹¹ and Shephard Mpofu¹², ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, United Kingdom, ³Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁸University of Queensland, Brisbane, Australia, ⁹Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose Secukinumab has demonstrated significant and rapid efficacy in the treatment of psoriasis in two phase 3 studies. We present the first randomized, multicenter, double-blind,…
Abstract Number: 1853 • 2014 ACR/ARHP Annual Meeting
Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Philip J. Mease¹, David Collier², Chitra Karki³, Guo Li⁴, Bojena Bitman⁵ and Jeffrey D. Greenberg^3,6, ¹Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Amgen, Inc., San Francisco, CA, ⁶Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Registry data regarding biologic DMARD therapy as a mono or combo (combined with a traditional oral DMARD) in subjects with Psoriatic Arthritis (PsA) are…
Abstract Number: 956 • 2014 ACR/ARHP Annual Meeting
Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Proton Rahman¹, Saeed Shaikh², Michael Starr³, William Bensen⁴, Denis Choquette⁵, Wojciech Olszynski⁶, Maqbool Sheriff⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, Allen J Lehman¹⁰, Susan Otawa¹⁰, Francois Nantel¹¹, Vincent Letourneau¹¹ and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²McMaster University, Hamilton, ON, Canada, ³Montreal General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸Université de Montréal, Montreal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada
Background/Purpose A definition of minimal disease activity (MDA) in PsA was derived from the opinion of 60 PsA experts including fulfillment of ≥5 of the…
Abstract Number: 1597 • 2014 ACR/ARHP Annual Meeting
Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Frank Zhang¹, Thomas Tencer¹, Stan Li² and Vibeke Strand³, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²Celgene Corporation, Warren, NJ, ³Biopharmaceutical Consultant, Portola Valley, CA
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the aberrant immune response that causes the joint symptoms, systemic inflammation, and skin…
Abstract Number: 955 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial
Peter Schafer¹, Peng Chen², Lorraine Fang², Andrew Wang² and Rajesh Chopra³, ¹Department of Translational Development, Celgene Corporation, Summit, NJ, ²Biostatistics, Celgene Corporation, Warren, NJ, ³Translational Development, Celgene Corporation, Summit, NJ
Background/Purpose Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].